Skip to ContentSkip to Navigation
Over ons Faculty of Science and Engineering Our Research GRIP Nanomedicine and Drug Targeting Publications

Publicaties 2006

Wetenschappelijke Publicaties in 2006
  1. Gonzalo T, Talman EG, van de Ven A, Temming K, Greupink R, Beljaars L, Reker-Smit C, Meijer DKF, Molema G, Poelstra K, Kok RJ. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. Journal of Controlled Release, 2006; 111(1-2):193-203. DOI

  2. Proost JH, Beljaars L, Olinga P, Swart PJ, Kuipers ME, Reker-Smit C, Groothuis GMM, Meijer DKF.  Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations. European Journal of Pharmaceutical Sciences, 2006; 27(2-3):123-132. DOI

  3. Adrian JE, Poelstra K, Scherphof GL, Molema G, Meijer DKF, Reker-Smit C, Morselt HWM, Kamps JAAM. Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems. Journal of Hepatology, 2006; 44(3):560-567. DOI

  4. Everts M, Saini V, Leddon JL, Kok RJ, Stoff-Khalili M, Preuss MA, Millican CL, Perkins G, Brown JM, Bagaria H, Nikles DE, Johnson DT, Zharov VP, Curiel DT. Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Letters, 2006; 6(4):587-591. DOI

  5. Koning GA, Schiffelers RM, Wauben MHM, Kok RJ, Mastrobattista E, Molema G, ten Hagen TLM, Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis & Rheumatism, 2006; 54(4):1198-1208. DOI

  6. Rots MG, Elferink MGL, Gommans WM, Oosterhuis D, Schalk JAC, Curiel DT, Olinga P, Haisma HJ, Groothuis GMM . An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. The Journal of Gene Medicine, 2006; 8(1):35-41. DOI

  7. Tuin A, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DKF, Poelstra K. On the role and fate of LPS-dephosphorylating activity in the rat liver. American Journal of Physiology - Gastrointestinal and Liver Physiology, 2006; 290(2):G377-G385. DOI

  8. van de Bovenkamp M, Groothuis GMM, Meijer DKF, Sloof MJH, Olinga P. Human liver slices as an in vitro model to study toxicity-induced hepatic stellate cell activation in a multicellular milieu. Chemico-Biological Interactions, 2006; 162(1):62-69. DOI

  9. Greupink R, Bakker HI, van Goor H, de Borst MH, Beljaars L, Poelstra K. Mannose-6-phosphate/insuline-like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells. Pharmaceutical Research, 2006; 23(8):1827-1834. DOI

  10. Proost JH. Pharmacokinetic simulations and AUC: center specificity in the limited sampling model. International Journal of Clinical Pharmacology and Therapeutics, 2006; 44(6):292-293. Letter to the Editor DOI

  11. van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P . Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro. Journal of Hepatology, 2006; 45(5):696-703. DOI

  12. de Graaf IAM, de Kanter R, de Jager MH, Camacho R, Langenkamp E, van de Kerkhof EG, Groothuis GMM . Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metabolism and Disposition, 2006; 34(4):591-599. DOI

  13. van de Kerkhof EG, Ungell A-LB, Sjöberg AK, de Jager MH, Hilgendorf C, de Graaf IAM, Groothuis GMM . Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations. Drug Metabolism and Disposition, 2006; 34(11):1893-1902 DOI

  14. Proost JH, Eleveld DJ . Parametric and nonparametric population methods. Clinical Pharmacokinetics, 2006; 45(8):851-852.
    Correspondence DOI

  15. Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers ECF, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ . Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug--albumin conjugates using platinum(II)-based drug linker technology. Bioconjugate Chemistry, 2006; 17(5):1246-1255. DOI

  16. Temming K, Meyer DL, Zabinski R, Dijkers ECF, Poelstra K, Molema G, Kok RJ . Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjugate Chemistry, 2006; 17(6):1385-1394. DOI

  17. Temming K, Lacombe M, Schaapveld RQJ, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. ChemMedChem, 2006; 1(11):1200-1203.
    Supporting Information on: rational design of RGD-albumin conjugates for targeted delivery of PTK787.
    DOI

  18. Hagens WI, Olinga P, Meijer DKF, Groothuis GMM, Beljaars L, Poelstra K . Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers. Liver International, 2006; 26(2):232-239. DOI

  19. Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion on Drug Metabolism and Toxicology, 2006; 2(6):875-894. DOI

  20. Martignoni M, Groothuis G, de Kanter R. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metabolism and Disposition, 2006; 34(6):1047-1054. DOI

  21. Greupink R, Bakker HI, Bouma W, Reker-Smit C, Meijer DKF, Beljaars L, Poelstra K. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. The Journal of Pharmacology and Experimental Therapeutics, 2006; 317(2):514-521. DOI

  22. Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQJ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Këri G, Meijer DKF, Poelstra K, Kok RJ. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. The Journal of Pharmacology and Experimental Therapeutics, 2006; 319(1):8-19. DOI

  23. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. The Journal of Rheumatology, 2006; 33(3):481-485.

  24. Proost JH, Eleveld DJ. Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets. Pharmaceutical Research, 2006; 23(12):2748-2759. Erratum appeared in: Pharmaceutical Research, 2007; 24(8): 1599 DOI

Hoofdstukken in boeken in 2006
  1. Beljaars L, Meijer DKF, Poelstra K. Drug targeting to hepatic stellate cells: a new strategy to treat liver fibrosis. In: Liver Diseases. Biochemical mechanisms and new therapeutic insights. Vol. 2 Pathophysiology, diagnostic and therapeutic insights, Chapt. 25, Ali S, Friedman SL, Mann DA, editors. Science Publishers, Enfield, New Hampshire, USA, 2006: 459-474. ISBN:1-57808-401-6

  2. Henning RH, Proost JH, de Graeff PA. Farmacodynamiek. In: Algemene Farmacologie. Chapt. 7, van Ree JM, Breimer DD, editors. Elsevier Gezondheidszorg, Maarssen, 2006: 125-157. ISBN: 90-352-2866-9

  3. Groothuis G, van der Valk J. Onderzoek met menselijk weefsel: een humaan alternatief? In: Kan het ook anders? Beschouwingen over alternatieven voor dierproeven. Swart J, Groothuis G, Horbach J, van der Valk J, editors. Uitgeverij DAMON bv, Budel, 2006: 80-89. ISBN: 90-5573-734-8

Professionele Publicaties in 2006
  1. Poelstra K, Molema G. De kunst van het raakschieten. Broerstraat 5, RUG, Groningen 2006; (April):16-17

Laatst gewijzigd:05 maart 2024 14:53
View this page in: English